International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment

Meletios A Dimopoulos; Pieter Sonneveld; Nelson Leung; Giampaolo Merlini; Heinz Ludwig; Efstathios Kastritis; Hartmut Goldschmidt; Douglas Joshua; Robert Z Orlowski; Raymond Powles; David H Vesole; Laurent Garderet; Hermann Einsele; Antonio Palumbo; Michele Cavo; Paul G Richardson; Philippe Moreau; Jesús San Miguel; S Vincent Rajkumar; Brian G M Durie; Evangelos Terpos

doi:10.1200/JCO.2015.65.0044

Back

International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment

Journal article

Peer reviewed

International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment

Meletios A Dimopoulos, Pieter Sonneveld, Nelson Leung, Giampaolo Merlini, Heinz Ludwig, Efstathios Kastritis, Hartmut Goldschmidt, Douglas Joshua, Robert Z Orlowski, Raymond Powles, …

Journal of clinical oncology, Vol.34(13), pp.1544-1557

2016-05-01

DOI: https://doi.org/10.1200/JCO.2015.65.0044

PMID: 26976420

Abstract

Humans

Multiple Myeloma - diagnosis

Multiple Myeloma - physiopathology

Multiple Myeloma - therapy

Renal Insufficiency - diagnosis

Renal Insufficiency - physiopathology

Renal Insufficiency - therapy

The aim of the International Myeloma Working Group was to develop practical recommendations for the diagnosis and management of multiple myeloma-related renal impairment (RI). Recommendations were based on published data through December 2015, and were developed using the system developed by the Grading of Recommendation, Assessment, Development, and Evaluation Working Group. All patients with myeloma at diagnosis and at disease assessment should have serum creatinine, estimated glomerular filtration rate, and electrolytes measurements as well as free light chain, if available, and urine electrophoresis of a sample from a 24-hour urine collection (grade A). The Chronic Kidney Disease Epidemiology Collaboration, preferably, or the Modification of Diet in Renal Disease formula should be used for the evaluation of estimated glomerular filtration rate in patients with stabilized serum creatinine (grade A). International Myeloma Working Group criteria for renal reversibility should be used (grade B). For the management of RI in patients with multiple myeloma, high fluid intake is indicated along with antimyeloma therapy (grade B). The use of high-cutoff hemodialysis membranes in combination with antimyeloma therapy can be considered (grade B). Bortezomib-based regimens remain the cornerstone of the management of myeloma-related RI (grade A). High-dose dexamethasone should be administered at least for the first month of therapy (grade B). Thalidomide is effective in patients with myeloma with RI, and no dose modifications are needed (grade B). Lenalidomide is effective and safe, mainly in patients with mild to moderate RI (grade B); for patients with severe RI or on dialysis, lenalidomide should be given with close monitoring for hematologic toxicity (grade B) with dose reduction as needed. High-dose therapy with autologous stem cell transplantation (with melphalan 100 mg/m(2) to 140 mg/m(2)) is feasible in patients with RI (grade C). Carfilzomib can be safely administered to patients with creatinine clearance > 15 mL/min, whereas ixazomib in combination with lenalidomide and dexamethasone can be safely administered to patients with creatinine clearance > 30 mL/min (grade A).

Metrics

321 Record Views

252 Times Cited - Web of Science

See more details

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Highly Cited Paper

Collaboration types: Domestic collaboration; International collaboration
Citation topics: 1 Clinical & Life Sciences; 1.130 Lymphomas; 1.130.617 Multiple Myeloma
Web Of Science research areas: Oncology
ESI research areas: Clinical Medicine

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

Source: InCites

Details

Title: International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment
Creators: Meletios A Dimopoulos - Meletios A. Dimopoulos, Efstathios Kastritis, and Evangelos Terpos, National and Kapodistrian University of Athens, Athens, Greece; Pieter Sonneveld, Erasmus University Medical Center Rotterdam, Rotterdam, the Netherlands; Nelson Leung and S. Vincent Rajkumar, Mayo Clinic, Rochester, MN; Robert Z. Orlowski, The University of Texas MD Anderson Cancer Center, Houston, TX; David H. Vesole, Hackensack University Medical Center, Hackensack, NJ; Paul G. Richardson, Dana-Farber Cancer Institute, Boston, MA; Brian G.M. Durie, Samuel Oschin Cancer Center, Los Angeles, CA; Giampaolo Merlini, Scientific Institute Policlinico San Matteo and University of Pavia, Pavia; Antonio Palumbo, University of Torino, Azienda Ospedaliero-Universitaria Citta della Salute e della Scienza di Torino, Torino; Michele Cavo, Bologna University School of Medicine, S.Orsola's University Hospital, Bologna, Italy; Heinz Ludwig, Wilhelminenspital, Vienna, Austria; Hartmut Goldschmidt, University Hospital and National Center for Tumor Diseases Heidelberg, Heidelberg; Hermann Einsele, Wuerzburg University Medical Center, Wuerzburg, Germany; Douglas Joshua, Royal Prince Alfred Hospital, Sydney University Medical School, Sydney, New South Wales, Australia; Raymond Powles, Cancer Centre London, London, United Kingdom; Laurent Garderet, Saint Antoine Hospital & University of "Pierre et Marie Curie" Paris-6, Paris; Philippe Moreau, University Hospital Hôtel-Dieu, Nantes, France; and Jesús San Miguel, Clínica Universidad de Navarra/CIMA, Navarra, Spain. mdimop@med.uoa.gr
Pieter Sonneveld - Meletios A. Dimopoulos, Efstathios Kastritis, and Evangelos Terpos, National and Kapodistrian University of Athens, Athens, Greece; Pieter Sonneveld, Erasmus University Medical Center Rotterdam, Rotterdam, the Netherlands; Nelson Leung and S. Vincent Rajkumar, Mayo Clinic, Rochester, MN; Robert Z. Orlowski, The University of Texas MD Anderson Cancer Center, Houston, TX; David H. Vesole, Hackensack University Medical Center, Hackensack, NJ; Paul G. Richardson, Dana-Farber Cancer Institute, Boston, MA; Brian G.M. Durie, Samuel Oschin Cancer Center, Los Angeles, CA; Giampaolo Merlini, Scientific Institute Policlinico San Matteo and University of Pavia, Pavia; Antonio Palumbo, University of Torino, Azienda Ospedaliero-Universitaria Citta della Salute e della Scienza di Torino, Torino; Michele Cavo, Bologna University School of Medicine, S.Orsola's University Hospital, Bologna, Italy; Heinz Ludwig, Wilhelminenspital, Vienna, Austria; Hartmut Goldschmidt, University Hospital and National Center for Tumor Diseases Heidelberg, Heidelberg; Hermann Einsele, Wuerzburg University Medical Center, Wuerzburg, Germany; Douglas Joshua, Royal Prince Alfred Hospital, Sydney University Medical School, Sydney, New South Wales, Australia; Raymond Powles, Cancer Centre London, London, United Kingdom; Laurent Garderet, Saint Antoine Hospital & University of "Pierre et Marie Curie" Paris-6, Paris; Philippe Moreau, University Hospital Hôtel-Dieu, Nantes, France; and Jesús San Miguel, Clínica Universidad de Navarra/CIMA, Navarra, Spain
Nelson Leung - Meletios A. Dimopoulos, Efstathios Kastritis, and Evangelos Terpos, National and Kapodistrian University of Athens, Athens, Greece; Pieter Sonneveld, Erasmus University Medical Center Rotterdam, Rotterdam, the Netherlands; Nelson Leung and S. Vincent Rajkumar, Mayo Clinic, Rochester, MN; Robert Z. Orlowski, The University of Texas MD Anderson Cancer Center, Houston, TX; David H. Vesole, Hackensack University Medical Center, Hackensack, NJ; Paul G. Richardson, Dana-Farber Cancer Institute, Boston, MA; Brian G.M. Durie, Samuel Oschin Cancer Center, Los Angeles, CA; Giampaolo Merlini, Scientific Institute Policlinico San Matteo and University of Pavia, Pavia; Antonio Palumbo, University of Torino, Azienda Ospedaliero-Universitaria Citta della Salute e della Scienza di Torino, Torino; Michele Cavo, Bologna University School of Medicine, S.Orsola's University Hospital, Bologna, Italy; Heinz Ludwig, Wilhelminenspital, Vienna, Austria; Hartmut Goldschmidt, University Hospital and National Center for Tumor Diseases Heidelberg, Heidelberg; Hermann Einsele, Wuerzburg University Medical Center, Wuerzburg, Germany; Douglas Joshua, Royal Prince Alfred Hospital, Sydney University Medical School, Sydney, New South Wales, Australia; Raymond Powles, Cancer Centre London, London, United Kingdom; Laurent Garderet, Saint Antoine Hospital & University of "Pierre et Marie Curie" Paris-6, Paris; Philippe Moreau, University Hospital Hôtel-Dieu, Nantes, France; and Jesús San Miguel, Clínica Universidad de Navarra/CIMA, Navarra, Spain
Giampaolo Merlini - Meletios A. Dimopoulos, Efstathios Kastritis, and Evangelos Terpos, National and Kapodistrian University of Athens, Athens, Greece; Pieter Sonneveld, Erasmus University Medical Center Rotterdam, Rotterdam, the Netherlands; Nelson Leung and S. Vincent Rajkumar, Mayo Clinic, Rochester, MN; Robert Z. Orlowski, The University of Texas MD Anderson Cancer Center, Houston, TX; David H. Vesole, Hackensack University Medical Center, Hackensack, NJ; Paul G. Richardson, Dana-Farber Cancer Institute, Boston, MA; Brian G.M. Durie, Samuel Oschin Cancer Center, Los Angeles, CA; Giampaolo Merlini, Scientific Institute Policlinico San Matteo and University of Pavia, Pavia; Antonio Palumbo, University of Torino, Azienda Ospedaliero-Universitaria Citta della Salute e della Scienza di Torino, Torino; Michele Cavo, Bologna University School of Medicine, S.Orsola's University Hospital, Bologna, Italy; Heinz Ludwig, Wilhelminenspital, Vienna, Austria; Hartmut Goldschmidt, University Hospital and National Center for Tumor Diseases Heidelberg, Heidelberg; Hermann Einsele, Wuerzburg University Medical Center, Wuerzburg, Germany; Douglas Joshua, Royal Prince Alfred Hospital, Sydney University Medical School, Sydney, New South Wales, Australia; Raymond Powles, Cancer Centre London, London, United Kingdom; Laurent Garderet, Saint Antoine Hospital & University of "Pierre et Marie Curie" Paris-6, Paris; Philippe Moreau, University Hospital Hôtel-Dieu, Nantes, France; and Jesús San Miguel, Clínica Universidad de Navarra/CIMA, Navarra, Spain
Heinz Ludwig - Meletios A. Dimopoulos, Efstathios Kastritis, and Evangelos Terpos, National and Kapodistrian University of Athens, Athens, Greece; Pieter Sonneveld, Erasmus University Medical Center Rotterdam, Rotterdam, the Netherlands; Nelson Leung and S. Vincent Rajkumar, Mayo Clinic, Rochester, MN; Robert Z. Orlowski, The University of Texas MD Anderson Cancer Center, Houston, TX; David H. Vesole, Hackensack University Medical Center, Hackensack, NJ; Paul G. Richardson, Dana-Farber Cancer Institute, Boston, MA; Brian G.M. Durie, Samuel Oschin Cancer Center, Los Angeles, CA; Giampaolo Merlini, Scientific Institute Policlinico San Matteo and University of Pavia, Pavia; Antonio Palumbo, University of Torino, Azienda Ospedaliero-Universitaria Citta della Salute e della Scienza di Torino, Torino; Michele Cavo, Bologna University School of Medicine, S.Orsola's University Hospital, Bologna, Italy; Heinz Ludwig, Wilhelminenspital, Vienna, Austria; Hartmut Goldschmidt, University Hospital and National Center for Tumor Diseases Heidelberg, Heidelberg; Hermann Einsele, Wuerzburg University Medical Center, Wuerzburg, Germany; Douglas Joshua, Royal Prince Alfred Hospital, Sydney University Medical School, Sydney, New South Wales, Australia; Raymond Powles, Cancer Centre London, London, United Kingdom; Laurent Garderet, Saint Antoine Hospital & University of "Pierre et Marie Curie" Paris-6, Paris; Philippe Moreau, University Hospital Hôtel-Dieu, Nantes, France; and Jesús San Miguel, Clínica Universidad de Navarra/CIMA, Navarra, Spain
Efstathios Kastritis - Meletios A. Dimopoulos, Efstathios Kastritis, and Evangelos Terpos, National and Kapodistrian University of Athens, Athens, Greece; Pieter Sonneveld, Erasmus University Medical Center Rotterdam, Rotterdam, the Netherlands; Nelson Leung and S. Vincent Rajkumar, Mayo Clinic, Rochester, MN; Robert Z. Orlowski, The University of Texas MD Anderson Cancer Center, Houston, TX; David H. Vesole, Hackensack University Medical Center, Hackensack, NJ; Paul G. Richardson, Dana-Farber Cancer Institute, Boston, MA; Brian G.M. Durie, Samuel Oschin Cancer Center, Los Angeles, CA; Giampaolo Merlini, Scientific Institute Policlinico San Matteo and University of Pavia, Pavia; Antonio Palumbo, University of Torino, Azienda Ospedaliero-Universitaria Citta della Salute e della Scienza di Torino, Torino; Michele Cavo, Bologna University School of Medicine, S.Orsola's University Hospital, Bologna, Italy; Heinz Ludwig, Wilhelminenspital, Vienna, Austria; Hartmut Goldschmidt, University Hospital and National Center for Tumor Diseases Heidelberg, Heidelberg; Hermann Einsele, Wuerzburg University Medical Center, Wuerzburg, Germany; Douglas Joshua, Royal Prince Alfred Hospital, Sydney University Medical School, Sydney, New South Wales, Australia; Raymond Powles, Cancer Centre London, London, United Kingdom; Laurent Garderet, Saint Antoine Hospital & University of "Pierre et Marie Curie" Paris-6, Paris; Philippe Moreau, University Hospital Hôtel-Dieu, Nantes, France; and Jesús San Miguel, Clínica Universidad de Navarra/CIMA, Navarra, Spain
Hartmut Goldschmidt - Meletios A. Dimopoulos, Efstathios Kastritis, and Evangelos Terpos, National and Kapodistrian University of Athens, Athens, Greece; Pieter Sonneveld, Erasmus University Medical Center Rotterdam, Rotterdam, the Netherlands; Nelson Leung and S. Vincent Rajkumar, Mayo Clinic, Rochester, MN; Robert Z. Orlowski, The University of Texas MD Anderson Cancer Center, Houston, TX; David H. Vesole, Hackensack University Medical Center, Hackensack, NJ; Paul G. Richardson, Dana-Farber Cancer Institute, Boston, MA; Brian G.M. Durie, Samuel Oschin Cancer Center, Los Angeles, CA; Giampaolo Merlini, Scientific Institute Policlinico San Matteo and University of Pavia, Pavia; Antonio Palumbo, University of Torino, Azienda Ospedaliero-Universitaria Citta della Salute e della Scienza di Torino, Torino; Michele Cavo, Bologna University School of Medicine, S.Orsola's University Hospital, Bologna, Italy; Heinz Ludwig, Wilhelminenspital, Vienna, Austria; Hartmut Goldschmidt, University Hospital and National Center for Tumor Diseases Heidelberg, Heidelberg; Hermann Einsele, Wuerzburg University Medical Center, Wuerzburg, Germany; Douglas Joshua, Royal Prince Alfred Hospital, Sydney University Medical School, Sydney, New South Wales, Australia; Raymond Powles, Cancer Centre London, London, United Kingdom; Laurent Garderet, Saint Antoine Hospital & University of "Pierre et Marie Curie" Paris-6, Paris; Philippe Moreau, University Hospital Hôtel-Dieu, Nantes, France; and Jesús San Miguel, Clínica Universidad de Navarra/CIMA, Navarra, Spain
Douglas Joshua - Meletios A. Dimopoulos, Efstathios Kastritis, and Evangelos Terpos, National and Kapodistrian University of Athens, Athens, Greece; Pieter Sonneveld, Erasmus University Medical Center Rotterdam, Rotterdam, the Netherlands; Nelson Leung and S. Vincent Rajkumar, Mayo Clinic, Rochester, MN; Robert Z. Orlowski, The University of Texas MD Anderson Cancer Center, Houston, TX; David H. Vesole, Hackensack University Medical Center, Hackensack, NJ; Paul G. Richardson, Dana-Farber Cancer Institute, Boston, MA; Brian G.M. Durie, Samuel Oschin Cancer Center, Los Angeles, CA; Giampaolo Merlini, Scientific Institute Policlinico San Matteo and University of Pavia, Pavia; Antonio Palumbo, University of Torino, Azienda Ospedaliero-Universitaria Citta della Salute e della Scienza di Torino, Torino; Michele Cavo, Bologna University School of Medicine, S.Orsola's University Hospital, Bologna, Italy; Heinz Ludwig, Wilhelminenspital, Vienna, Austria; Hartmut Goldschmidt, University Hospital and National Center for Tumor Diseases Heidelberg, Heidelberg; Hermann Einsele, Wuerzburg University Medical Center, Wuerzburg, Germany; Douglas Joshua, Royal Prince Alfred Hospital, Sydney University Medical School, Sydney, New South Wales, Australia; Raymond Powles, Cancer Centre London, London, United Kingdom; Laurent Garderet, Saint Antoine Hospital & University of "Pierre et Marie Curie" Paris-6, Paris; Philippe Moreau, University Hospital Hôtel-Dieu, Nantes, France; and Jesús San Miguel, Clínica Universidad de Navarra/CIMA, Navarra, Spain
Robert Z Orlowski - Meletios A. Dimopoulos, Efstathios Kastritis, and Evangelos Terpos, National and Kapodistrian University of Athens, Athens, Greece; Pieter Sonneveld, Erasmus University Medical Center Rotterdam, Rotterdam, the Netherlands; Nelson Leung and S. Vincent Rajkumar, Mayo Clinic, Rochester, MN; Robert Z. Orlowski, The University of Texas MD Anderson Cancer Center, Houston, TX; David H. Vesole, Hackensack University Medical Center, Hackensack, NJ; Paul G. Richardson, Dana-Farber Cancer Institute, Boston, MA; Brian G.M. Durie, Samuel Oschin Cancer Center, Los Angeles, CA; Giampaolo Merlini, Scientific Institute Policlinico San Matteo and University of Pavia, Pavia; Antonio Palumbo, University of Torino, Azienda Ospedaliero-Universitaria Citta della Salute e della Scienza di Torino, Torino; Michele Cavo, Bologna University School of Medicine, S.Orsola's University Hospital, Bologna, Italy; Heinz Ludwig, Wilhelminenspital, Vienna, Austria; Hartmut Goldschmidt, University Hospital and National Center for Tumor Diseases Heidelberg, Heidelberg; Hermann Einsele, Wuerzburg University Medical Center, Wuerzburg, Germany; Douglas Joshua, Royal Prince Alfred Hospital, Sydney University Medical School, Sydney, New South Wales, Australia; Raymond Powles, Cancer Centre London, London, United Kingdom; Laurent Garderet, Saint Antoine Hospital & University of "Pierre et Marie Curie" Paris-6, Paris; Philippe Moreau, University Hospital Hôtel-Dieu, Nantes, France; and Jesús San Miguel, Clínica Universidad de Navarra/CIMA, Navarra, Spain
Raymond Powles - Meletios A. Dimopoulos, Efstathios Kastritis, and Evangelos Terpos, National and Kapodistrian University of Athens, Athens, Greece; Pieter Sonneveld, Erasmus University Medical Center Rotterdam, Rotterdam, the Netherlands; Nelson Leung and S. Vincent Rajkumar, Mayo Clinic, Rochester, MN; Robert Z. Orlowski, The University of Texas MD Anderson Cancer Center, Houston, TX; David H. Vesole, Hackensack University Medical Center, Hackensack, NJ; Paul G. Richardson, Dana-Farber Cancer Institute, Boston, MA; Brian G.M. Durie, Samuel Oschin Cancer Center, Los Angeles, CA; Giampaolo Merlini, Scientific Institute Policlinico San Matteo and University of Pavia, Pavia; Antonio Palumbo, University of Torino, Azienda Ospedaliero-Universitaria Citta della Salute e della Scienza di Torino, Torino; Michele Cavo, Bologna University School of Medicine, S.Orsola's University Hospital, Bologna, Italy; Heinz Ludwig, Wilhelminenspital, Vienna, Austria; Hartmut Goldschmidt, University Hospital and National Center for Tumor Diseases Heidelberg, Heidelberg; Hermann Einsele, Wuerzburg University Medical Center, Wuerzburg, Germany; Douglas Joshua, Royal Prince Alfred Hospital, Sydney University Medical School, Sydney, New South Wales, Australia; Raymond Powles, Cancer Centre London, London, United Kingdom; Laurent Garderet, Saint Antoine Hospital & University of "Pierre et Marie Curie" Paris-6, Paris; Philippe Moreau, University Hospital Hôtel-Dieu, Nantes, France; and Jesús San Miguel, Clínica Universidad de Navarra/CIMA, Navarra, Spain
David H Vesole - Meletios A. Dimopoulos, Efstathios Kastritis, and Evangelos Terpos, National and Kapodistrian University of Athens, Athens, Greece; Pieter Sonneveld, Erasmus University Medical Center Rotterdam, Rotterdam, the Netherlands; Nelson Leung and S. Vincent Rajkumar, Mayo Clinic, Rochester, MN; Robert Z. Orlowski, The University of Texas MD Anderson Cancer Center, Houston, TX; David H. Vesole, Hackensack University Medical Center, Hackensack, NJ; Paul G. Richardson, Dana-Farber Cancer Institute, Boston, MA; Brian G.M. Durie, Samuel Oschin Cancer Center, Los Angeles, CA; Giampaolo Merlini, Scientific Institute Policlinico San Matteo and University of Pavia, Pavia; Antonio Palumbo, University of Torino, Azienda Ospedaliero-Universitaria Citta della Salute e della Scienza di Torino, Torino; Michele Cavo, Bologna University School of Medicine, S.Orsola's University Hospital, Bologna, Italy; Heinz Ludwig, Wilhelminenspital, Vienna, Austria; Hartmut Goldschmidt, University Hospital and National Center for Tumor Diseases Heidelberg, Heidelberg; Hermann Einsele, Wuerzburg University Medical Center, Wuerzburg, Germany; Douglas Joshua, Royal Prince Alfred Hospital, Sydney University Medical School, Sydney, New South Wales, Australia; Raymond Powles, Cancer Centre London, London, United Kingdom; Laurent Garderet, Saint Antoine Hospital & University of "Pierre et Marie Curie" Paris-6, Paris; Philippe Moreau, University Hospital Hôtel-Dieu, Nantes, France; and Jesús San Miguel, Clínica Universidad de Navarra/CIMA, Navarra, Spain
Laurent Garderet - Meletios A. Dimopoulos, Efstathios Kastritis, and Evangelos Terpos, National and Kapodistrian University of Athens, Athens, Greece; Pieter Sonneveld, Erasmus University Medical Center Rotterdam, Rotterdam, the Netherlands; Nelson Leung and S. Vincent Rajkumar, Mayo Clinic, Rochester, MN; Robert Z. Orlowski, The University of Texas MD Anderson Cancer Center, Houston, TX; David H. Vesole, Hackensack University Medical Center, Hackensack, NJ; Paul G. Richardson, Dana-Farber Cancer Institute, Boston, MA; Brian G.M. Durie, Samuel Oschin Cancer Center, Los Angeles, CA; Giampaolo Merlini, Scientific Institute Policlinico San Matteo and University of Pavia, Pavia; Antonio Palumbo, University of Torino, Azienda Ospedaliero-Universitaria Citta della Salute e della Scienza di Torino, Torino; Michele Cavo, Bologna University School of Medicine, S.Orsola's University Hospital, Bologna, Italy; Heinz Ludwig, Wilhelminenspital, Vienna, Austria; Hartmut Goldschmidt, University Hospital and National Center for Tumor Diseases Heidelberg, Heidelberg; Hermann Einsele, Wuerzburg University Medical Center, Wuerzburg, Germany; Douglas Joshua, Royal Prince Alfred Hospital, Sydney University Medical School, Sydney, New South Wales, Australia; Raymond Powles, Cancer Centre London, London, United Kingdom; Laurent Garderet, Saint Antoine Hospital & University of "Pierre et Marie Curie" Paris-6, Paris; Philippe Moreau, University Hospital Hôtel-Dieu, Nantes, France; and Jesús San Miguel, Clínica Universidad de Navarra/CIMA, Navarra, Spain
Hermann Einsele - Meletios A. Dimopoulos, Efstathios Kastritis, and Evangelos Terpos, National and Kapodistrian University of Athens, Athens, Greece; Pieter Sonneveld, Erasmus University Medical Center Rotterdam, Rotterdam, the Netherlands; Nelson Leung and S. Vincent Rajkumar, Mayo Clinic, Rochester, MN; Robert Z. Orlowski, The University of Texas MD Anderson Cancer Center, Houston, TX; David H. Vesole, Hackensack University Medical Center, Hackensack, NJ; Paul G. Richardson, Dana-Farber Cancer Institute, Boston, MA; Brian G.M. Durie, Samuel Oschin Cancer Center, Los Angeles, CA; Giampaolo Merlini, Scientific Institute Policlinico San Matteo and University of Pavia, Pavia; Antonio Palumbo, University of Torino, Azienda Ospedaliero-Universitaria Citta della Salute e della Scienza di Torino, Torino; Michele Cavo, Bologna University School of Medicine, S.Orsola's University Hospital, Bologna, Italy; Heinz Ludwig, Wilhelminenspital, Vienna, Austria; Hartmut Goldschmidt, University Hospital and National Center for Tumor Diseases Heidelberg, Heidelberg; Hermann Einsele, Wuerzburg University Medical Center, Wuerzburg, Germany; Douglas Joshua, Royal Prince Alfred Hospital, Sydney University Medical School, Sydney, New South Wales, Australia; Raymond Powles, Cancer Centre London, London, United Kingdom; Laurent Garderet, Saint Antoine Hospital & University of "Pierre et Marie Curie" Paris-6, Paris; Philippe Moreau, University Hospital Hôtel-Dieu, Nantes, France; and Jesús San Miguel, Clínica Universidad de Navarra/CIMA, Navarra, Spain
Antonio Palumbo - Meletios A. Dimopoulos, Efstathios Kastritis, and Evangelos Terpos, National and Kapodistrian University of Athens, Athens, Greece; Pieter Sonneveld, Erasmus University Medical Center Rotterdam, Rotterdam, the Netherlands; Nelson Leung and S. Vincent Rajkumar, Mayo Clinic, Rochester, MN; Robert Z. Orlowski, The University of Texas MD Anderson Cancer Center, Houston, TX; David H. Vesole, Hackensack University Medical Center, Hackensack, NJ; Paul G. Richardson, Dana-Farber Cancer Institute, Boston, MA; Brian G.M. Durie, Samuel Oschin Cancer Center, Los Angeles, CA; Giampaolo Merlini, Scientific Institute Policlinico San Matteo and University of Pavia, Pavia; Antonio Palumbo, University of Torino, Azienda Ospedaliero-Universitaria Citta della Salute e della Scienza di Torino, Torino; Michele Cavo, Bologna University School of Medicine, S.Orsola's University Hospital, Bologna, Italy; Heinz Ludwig, Wilhelminenspital, Vienna, Austria; Hartmut Goldschmidt, University Hospital and National Center for Tumor Diseases Heidelberg, Heidelberg; Hermann Einsele, Wuerzburg University Medical Center, Wuerzburg, Germany; Douglas Joshua, Royal Prince Alfred Hospital, Sydney University Medical School, Sydney, New South Wales, Australia; Raymond Powles, Cancer Centre London, London, United Kingdom; Laurent Garderet, Saint Antoine Hospital & University of "Pierre et Marie Curie" Paris-6, Paris; Philippe Moreau, University Hospital Hôtel-Dieu, Nantes, France; and Jesús San Miguel, Clínica Universidad de Navarra/CIMA, Navarra, Spain
Michele Cavo - Meletios A. Dimopoulos, Efstathios Kastritis, and Evangelos Terpos, National and Kapodistrian University of Athens, Athens, Greece; Pieter Sonneveld, Erasmus University Medical Center Rotterdam, Rotterdam, the Netherlands; Nelson Leung and S. Vincent Rajkumar, Mayo Clinic, Rochester, MN; Robert Z. Orlowski, The University of Texas MD Anderson Cancer Center, Houston, TX; David H. Vesole, Hackensack University Medical Center, Hackensack, NJ; Paul G. Richardson, Dana-Farber Cancer Institute, Boston, MA; Brian G.M. Durie, Samuel Oschin Cancer Center, Los Angeles, CA; Giampaolo Merlini, Scientific Institute Policlinico San Matteo and University of Pavia, Pavia; Antonio Palumbo, University of Torino, Azienda Ospedaliero-Universitaria Citta della Salute e della Scienza di Torino, Torino; Michele Cavo, Bologna University School of Medicine, S.Orsola's University Hospital, Bologna, Italy; Heinz Ludwig, Wilhelminenspital, Vienna, Austria; Hartmut Goldschmidt, University Hospital and National Center for Tumor Diseases Heidelberg, Heidelberg; Hermann Einsele, Wuerzburg University Medical Center, Wuerzburg, Germany; Douglas Joshua, Royal Prince Alfred Hospital, Sydney University Medical School, Sydney, New South Wales, Australia; Raymond Powles, Cancer Centre London, London, United Kingdom; Laurent Garderet, Saint Antoine Hospital & University of "Pierre et Marie Curie" Paris-6, Paris; Philippe Moreau, University Hospital Hôtel-Dieu, Nantes, France; and Jesús San Miguel, Clínica Universidad de Navarra/CIMA, Navarra, Spain
Paul G Richardson - Meletios A. Dimopoulos, Efstathios Kastritis, and Evangelos Terpos, National and Kapodistrian University of Athens, Athens, Greece; Pieter Sonneveld, Erasmus University Medical Center Rotterdam, Rotterdam, the Netherlands; Nelson Leung and S. Vincent Rajkumar, Mayo Clinic, Rochester, MN; Robert Z. Orlowski, The University of Texas MD Anderson Cancer Center, Houston, TX; David H. Vesole, Hackensack University Medical Center, Hackensack, NJ; Paul G. Richardson, Dana-Farber Cancer Institute, Boston, MA; Brian G.M. Durie, Samuel Oschin Cancer Center, Los Angeles, CA; Giampaolo Merlini, Scientific Institute Policlinico San Matteo and University of Pavia, Pavia; Antonio Palumbo, University of Torino, Azienda Ospedaliero-Universitaria Citta della Salute e della Scienza di Torino, Torino; Michele Cavo, Bologna University School of Medicine, S.Orsola's University Hospital, Bologna, Italy; Heinz Ludwig, Wilhelminenspital, Vienna, Austria; Hartmut Goldschmidt, University Hospital and National Center for Tumor Diseases Heidelberg, Heidelberg; Hermann Einsele, Wuerzburg University Medical Center, Wuerzburg, Germany; Douglas Joshua, Royal Prince Alfred Hospital, Sydney University Medical School, Sydney, New South Wales, Australia; Raymond Powles, Cancer Centre London, London, United Kingdom; Laurent Garderet, Saint Antoine Hospital & University of "Pierre et Marie Curie" Paris-6, Paris; Philippe Moreau, University Hospital Hôtel-Dieu, Nantes, France; and Jesús San Miguel, Clínica Universidad de Navarra/CIMA, Navarra, Spain
Philippe Moreau - Meletios A. Dimopoulos, Efstathios Kastritis, and Evangelos Terpos, National and Kapodistrian University of Athens, Athens, Greece; Pieter Sonneveld, Erasmus University Medical Center Rotterdam, Rotterdam, the Netherlands; Nelson Leung and S. Vincent Rajkumar, Mayo Clinic, Rochester, MN; Robert Z. Orlowski, The University of Texas MD Anderson Cancer Center, Houston, TX; David H. Vesole, Hackensack University Medical Center, Hackensack, NJ; Paul G. Richardson, Dana-Farber Cancer Institute, Boston, MA; Brian G.M. Durie, Samuel Oschin Cancer Center, Los Angeles, CA; Giampaolo Merlini, Scientific Institute Policlinico San Matteo and University of Pavia, Pavia; Antonio Palumbo, University of Torino, Azienda Ospedaliero-Universitaria Citta della Salute e della Scienza di Torino, Torino; Michele Cavo, Bologna University School of Medicine, S.Orsola's University Hospital, Bologna, Italy; Heinz Ludwig, Wilhelminenspital, Vienna, Austria; Hartmut Goldschmidt, University Hospital and National Center for Tumor Diseases Heidelberg, Heidelberg; Hermann Einsele, Wuerzburg University Medical Center, Wuerzburg, Germany; Douglas Joshua, Royal Prince Alfred Hospital, Sydney University Medical School, Sydney, New South Wales, Australia; Raymond Powles, Cancer Centre London, London, United Kingdom; Laurent Garderet, Saint Antoine Hospital & University of "Pierre et Marie Curie" Paris-6, Paris; Philippe Moreau, University Hospital Hôtel-Dieu, Nantes, France; and Jesús San Miguel, Clínica Universidad de Navarra/CIMA, Navarra, Spain
Jesús San Miguel - Meletios A. Dimopoulos, Efstathios Kastritis, and Evangelos Terpos, National and Kapodistrian University of Athens, Athens, Greece; Pieter Sonneveld, Erasmus University Medical Center Rotterdam, Rotterdam, the Netherlands; Nelson Leung and S. Vincent Rajkumar, Mayo Clinic, Rochester, MN; Robert Z. Orlowski, The University of Texas MD Anderson Cancer Center, Houston, TX; David H. Vesole, Hackensack University Medical Center, Hackensack, NJ; Paul G. Richardson, Dana-Farber Cancer Institute, Boston, MA; Brian G.M. Durie, Samuel Oschin Cancer Center, Los Angeles, CA; Giampaolo Merlini, Scientific Institute Policlinico San Matteo and University of Pavia, Pavia; Antonio Palumbo, University of Torino, Azienda Ospedaliero-Universitaria Citta della Salute e della Scienza di Torino, Torino; Michele Cavo, Bologna University School of Medicine, S.Orsola's University Hospital, Bologna, Italy; Heinz Ludwig, Wilhelminenspital, Vienna, Austria; Hartmut Goldschmidt, University Hospital and National Center for Tumor Diseases Heidelberg, Heidelberg; Hermann Einsele, Wuerzburg University Medical Center, Wuerzburg, Germany; Douglas Joshua, Royal Prince Alfred Hospital, Sydney University Medical School, Sydney, New South Wales, Australia; Raymond Powles, Cancer Centre London, London, United Kingdom; Laurent Garderet, Saint Antoine Hospital & University of "Pierre et Marie Curie" Paris-6, Paris; Philippe Moreau, University Hospital Hôtel-Dieu, Nantes, France; and Jesús San Miguel, Clínica Universidad de Navarra/CIMA, Navarra, Spain
S Vincent Rajkumar - Meletios A. Dimopoulos, Efstathios Kastritis, and Evangelos Terpos, National and Kapodistrian University of Athens, Athens, Greece; Pieter Sonneveld, Erasmus University Medical Center Rotterdam, Rotterdam, the Netherlands; Nelson Leung and S. Vincent Rajkumar, Mayo Clinic, Rochester, MN; Robert Z. Orlowski, The University of Texas MD Anderson Cancer Center, Houston, TX; David H. Vesole, Hackensack University Medical Center, Hackensack, NJ; Paul G. Richardson, Dana-Farber Cancer Institute, Boston, MA; Brian G.M. Durie, Samuel Oschin Cancer Center, Los Angeles, CA; Giampaolo Merlini, Scientific Institute Policlinico San Matteo and University of Pavia, Pavia; Antonio Palumbo, University of Torino, Azienda Ospedaliero-Universitaria Citta della Salute e della Scienza di Torino, Torino; Michele Cavo, Bologna University School of Medicine, S.Orsola's University Hospital, Bologna, Italy; Heinz Ludwig, Wilhelminenspital, Vienna, Austria; Hartmut Goldschmidt, University Hospital and National Center for Tumor Diseases Heidelberg, Heidelberg; Hermann Einsele, Wuerzburg University Medical Center, Wuerzburg, Germany; Douglas Joshua, Royal Prince Alfred Hospital, Sydney University Medical School, Sydney, New South Wales, Australia; Raymond Powles, Cancer Centre London, London, United Kingdom; Laurent Garderet, Saint Antoine Hospital & University of "Pierre et Marie Curie" Paris-6, Paris; Philippe Moreau, University Hospital Hôtel-Dieu, Nantes, France; and Jesús San Miguel, Clínica Universidad de Navarra/CIMA, Navarra, Spain
Brian G M Durie - Meletios A. Dimopoulos, Efstathios Kastritis, and Evangelos Terpos, National and Kapodistrian University of Athens, Athens, Greece; Pieter Sonneveld, Erasmus University Medical Center Rotterdam, Rotterdam, the Netherlands; Nelson Leung and S. Vincent Rajkumar, Mayo Clinic, Rochester, MN; Robert Z. Orlowski, The University of Texas MD Anderson Cancer Center, Houston, TX; David H. Vesole, Hackensack University Medical Center, Hackensack, NJ; Paul G. Richardson, Dana-Farber Cancer Institute, Boston, MA; Brian G.M. Durie, Samuel Oschin Cancer Center, Los Angeles, CA; Giampaolo Merlini, Scientific Institute Policlinico San Matteo and University of Pavia, Pavia; Antonio Palumbo, University of Torino, Azienda Ospedaliero-Universitaria Citta della Salute e della Scienza di Torino, Torino; Michele Cavo, Bologna University School of Medicine, S.Orsola's University Hospital, Bologna, Italy; Heinz Ludwig, Wilhelminenspital, Vienna, Austria; Hartmut Goldschmidt, University Hospital and National Center for Tumor Diseases Heidelberg, Heidelberg; Hermann Einsele, Wuerzburg University Medical Center, Wuerzburg, Germany; Douglas Joshua, Royal Prince Alfred Hospital, Sydney University Medical School, Sydney, New South Wales, Australia; Raymond Powles, Cancer Centre London, London, United Kingdom; Laurent Garderet, Saint Antoine Hospital & University of "Pierre et Marie Curie" Paris-6, Paris; Philippe Moreau, University Hospital Hôtel-Dieu, Nantes, France; and Jesús San Miguel, Clínica Universidad de Navarra/CIMA, Navarra, Spain
Evangelos Terpos - Meletios A. Dimopoulos, Efstathios Kastritis, and Evangelos Terpos, National and Kapodistrian University of Athens, Athens, Greece; Pieter Sonneveld, Erasmus University Medical Center Rotterdam, Rotterdam, the Netherlands; Nelson Leung and S. Vincent Rajkumar, Mayo Clinic, Rochester, MN; Robert Z. Orlowski, The University of Texas MD Anderson Cancer Center, Houston, TX; David H. Vesole, Hackensack University Medical Center, Hackensack, NJ; Paul G. Richardson, Dana-Farber Cancer Institute, Boston, MA; Brian G.M. Durie, Samuel Oschin Cancer Center, Los Angeles, CA; Giampaolo Merlini, Scientific Institute Policlinico San Matteo and University of Pavia, Pavia; Antonio Palumbo, University of Torino, Azienda Ospedaliero-Universitaria Citta della Salute e della Scienza di Torino, Torino; Michele Cavo, Bologna University School of Medicine, S.Orsola's University Hospital, Bologna, Italy; Heinz Ludwig, Wilhelminenspital, Vienna, Austria; Hartmut Goldschmidt, University Hospital and National Center for Tumor Diseases Heidelberg, Heidelberg; Hermann Einsele, Wuerzburg University Medical Center, Wuerzburg, Germany; Douglas Joshua, Royal Prince Alfred Hospital, Sydney University Medical School, Sydney, New South Wales, Australia; Raymond Powles, Cancer Centre London, London, United Kingdom; Laurent Garderet, Saint Antoine Hospital & University of "Pierre et Marie Curie" Paris-6, Paris; Philippe Moreau, University Hospital Hôtel-Dieu, Nantes, France; and Jesús San Miguel, Clínica Universidad de Navarra/CIMA, Navarra, Spain
Publication Details: Journal of clinical oncology, Vol.34(13), pp.1544-1557
Language: English
Resource Type: Journal article
PMID: 26976420
Record Identifier: 991031615098802976